Objective:To explore the effect of hyperbaric oxygen combined with papaverine in the treatment of non-gangrenous ischemic colitis.Methods:A total of 94 cases of non-gangrenous ischemic colitis admitted to the Department of Gastroenterology of Zhoushan Women and Children Hospital from January 2018 to June 2019 were randomly divided into hyperbaric oxygen treatment group and control group with 47 cases in each group. The control group received conventional symptomatic supportive treatment and papaverine treatment, and the hyperbaric oxygen treatment group received conventional symptomatic supportive treatment and hyperbaric oxygen combined with papaverine treatment. Both two groups received continuous treatment for 2 weeks. The clinical indicators, hemorheological indicators, serum superoxide dismutase (SOD) activity, adverse reactions, and clinical efficacies of the two groups were compared.Results:The clinical indicators such as the time to abdominal pain relief, the time to tenderness relief, the time to the disappearance of fecal occult blood, the time to intestinal function recovery, and the length of hospital stay, in the hyperbaric oxygen treatment group were significantly shorter than those in the control group ( P<0.01). After 2 weeks of treatment, the blood viscosity and the level of blood fibrinogen in the hyperbaric oxygen treatment group were significantly lower than those in the control group ( P<0.01), while the serum level of SOD was significantly higher than that in the control group ( P<0.01). During the treatment, there was no significant difference in gastrointestinal reactions, allergies, or other adverse reactions between the two groups ( P>0.05). The total effective rate of the hyperbaric oxygen treatment group was higher than that of the control group [95.74% (45/47) vs. 80.85% (38/47)]( P<0.05). Conclusion:Hyperbaric oxygen combined with papaverine in the treatment of non-gangrenous ischemic colitis can improve the clinical indicators and hemorheological indicators, and achieve obvious clinical efficacy with a satisfactory safety.

Objective:To explore the effect of hyperbaric oxygen combined with papaverine in the treatment of non-gangrenous ischemic colitis.Methods:A total of 94 cases of non-gangrenous ischemic colitis admitted to the Department of Gastroenterology of Zhoushan Women and Children Hospital from January 2018 to June 2019 were randomly divided into hyperbaric oxygen treatment group and control group with 47 cases in each group. The control group received conventional symptomatic supportive treatment and papaverine treatment, and the hyperbaric oxygen treatment group received conventional symptomatic supportive treatment and hyperbaric oxygen combined with papaverine treatment. Both two groups received continuous treatment for 2 weeks. The clinical indicators, hemorheological indicators, serum superoxide dismutase (SOD) activity, adverse reactions, and clinical efficacies of the two groups were compared.Results:The clinical indicators such as the time to abdominal pain relief, the time to tenderness relief, the time to the disappearance of fecal occult blood, the time to intestinal function recovery, and the length of hospital stay, in the hyperbaric oxygen treatment group were significantly shorter than those in the control group ( P<0.01). After 2 weeks of treatment, the blood viscosity and the level of blood fibrinogen in the hyperbaric oxygen treatment group were significantly lower than those in the control group ( P<0.01), while the serum level of SOD was significantly higher than that in the control group ( P<0.01). During the treatment, there was no significant difference in gastrointestinal reactions, allergies, or other adverse reactions between the two groups ( P>0.05). The total effective rate of the hyperbaric oxygen treatment group was higher than that of the control group [95.74% (45/47) vs. 80.85% (38/47)]( P<0.05). Conclusion:Hyperbaric oxygen combined with papaverine in the treatment of non-gangrenous ischemic colitis can improve the clinical indicators and hemorheological indicators, and achieve obvious clinical efficacy with a satisfactory safety.

Objective To study the expression levels of serum HSP70 and p53 in gastric cancer and its cor-relation with helicobacter pylori infection.Methods 50 patients with gastric cancer were selected as the research object.Among 50 cases,30 cases were stage Ⅰ -Ⅱ,20 cases were stage Ⅲ,22 cases were with lymph node metasta-sis and 28 cases were without lymph node metastasis.40 healthy subjects were selected as the healthy control group. The serum levels of HSP70 and p53 were detected.Results In the gastric cancer group,the serum levels of HSP70 and p53 were markedly higher than those of the healthy control group,and the difference was statistically significant (t =12.53,16.79,all P <0.01).Moreover,with progressing of clinical stage of gastric cancer,the serum levels of HSP70 and p53 showed a trend of increasing(t =4.68,5.29,all P <0.01).The serum expression levels of HSP70 and p53 in gastric cancer with lymph node metastasis were significantly higher than those of patients without lymph node metastasis and the difference was still statistically significant(t =3.82,4.39,all P <0.01).The serum levels of HSP70 and p53 in the gastric cancer group with Hp positive were much higher,compared to those of cases with Hp negative and the difference was also statistically significant(t =4.72,4.17,all P <0.01).Conclusion In the gastric cancer patients,the serum expression level of HSP70 and p53 are increased.The expression of HSP70 and p53 are closely related to the progress and prognosis of gastric cancer and Hp infection.

12,9.41%(148/1578);RDQ≤12,91.58%(1430/1578).Logistic multiple regression analysis of gastroesophageal reflux correlation factor studied:OR= 2.781.Conclusions The results showed:there were close correlation of high salt diet and GERED.